Germany's MorphoSys AG says that Japan's Shionogi has elected to extend its current license agreement covering the use of the former's HuCAL technology in drug discovery, for three additional years. Under the terms of the deal, Shionogi will continue to have the right to use MorphoSys' proprietary antibody library HuCAL GOLD for research purposes at one of its research sites. The German group will receive annual user fees from Shionogi for access to the HuCAL technology. Further financial details were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze